APG-3288 / Ascentage Pharma - LARVOL DELTA

A Study of APG-3288 in Relapsed/Refractory Blood Cancers (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Ascentage Pharma Group Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2026 ➔ Aug 2026

Enrollment open • Trial initiation date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome

BTK Degrader APG-3288:…Upcoming milestones (GlobeNewswire) - "Plan to commence a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies."

Trial status • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Small Lymphocytic Lymphoma • Waldenstrom Macroglobulinemia

A Study of APG-3288 in Relapsed/Refractory Blood Cancers (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Ascentage Pharma Group Inc.

New P1 trial • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Lymphoplasmacytic Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Waldenstrom Macroglobulinemia

Ascentage Pharma…announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies (GlobeNewswire) - "Ascentage Pharma will be conducting a multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies."

New P1 trial • Hematological Malignancies

Ascentage Pharma…announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration (FDA) and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies (GlobeNewswire) - "This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies."

IND • New P1 trial • Hematological Malignancies